Dicot AB announced that it's phase 1 study is now entering its second and final part. After the previously announced start of recruitment of participants to what is called MAD, the dosing itself is now ready to start, where the participants will receive multiple doses. The first participants in Dicot's second and final part of its phase 1 clinical trial will be dosed.

Initially, participants were given a single dose (called Single Ascending Dose, SAD). Now new participants will receive repeated dosing (Multiple Ascending Dose, MAD). The MAD part is planned to include around 25 participants who are divided into different dose groups where the dose gradually increases between the different groups.

After dosing, frequent safety checks are carried out where, among other things, blood samples, blood pressure and ECG are taken, which is the standard procedure for this type of first in human studies. This is a placebo-controlled phase 1 clinical trial with the primary objective to evaluate the safety profile of LIB-01 in humans. The entire study is double-blinded, which means that some participants receive LIB-01 and some receive a placebo, and that neither the participant nor the physician knows which of the two was dosed.